Vialox
A synthetic pentapeptide inspired by Temple Pit Viper venom that competitively blocks nicotinic acetylcholine receptors, reducing muscle contraction and expression wrinkles by up to 49% in 28 days.
What is Vialox?
Vialox (Pentapeptide-3) is a synthetic pentapeptide (GPRPA) developed by Pentapharm (now DSM) as a topical cosmeceutical for reducing expression wrinkles. It is a truncated fragment inspired by Waglerin-1, a 22-amino acid peptide from the Temple Pit Viper (Tropidolaemus wagleri). Vialox acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nAChR), blocking the signal that tells facial muscles to contract. In manufacturer testing, it reduced muscle contractions by 71% within one minute and 58% at two hours. A 28-day in vivo study showed 49% reduction in wrinkle depth and 47% reduction in skin roughness. Unlike injectable Botox, Vialox is applied topically with gentler, partial muscle relaxation.
What Vialox Is Investigated For
Vialox is investigated as a topical cosmeceutical anti-wrinkle active inspired by waglerin-1 Temple Pit Viper venom, acting as a postsynaptic nicotinic acetylcholine receptor competitive antagonist to reduce dynamic expression wrinkles. The strongest available evidence is a Pentapharm/DSM 28-day in vivo study (women aged 30–60, twice-daily application) reporting 49% wrinkle-depth reduction and 47% skin-roughness reduction, plus in vitro muscle contraction data (71% reduction at 1 minute, 58% at 2 hours). The honest caveats are significant. Efficacy claims rest almost entirely on manufacturer-sponsored studies that have not been independently replicated in peer-reviewed trials, and the headline 49% figure sits at the high end of cosmetic peptide claims — real-world effects at typical product concentrations are substantially more variable. The parent waglerin-1 peptide shows roughly 100-fold species selectivity favoring mouse over human nAChR, a caveat that complicates translation of in vitro receptor data, and whether the truncated synthetic pentapeptide actually reaches neuromuscular junctions in facial musculature at meaningful concentrations from topical application remains the central unresolved question. The 'natural Botox' marketing framing overstates magnitude — botulinum toxin injection produces 50–80% wrinkle reduction within days, not comparable to topical Vialox's softer, slower effect.
History & Discovery
Vialox was developed by Pentapharm (later DSM, now dsm-firmenich) in Switzerland in the early 2000s and trademarked as a synthetic biomimetic of waglerin-1, a 22-amino-acid peptide isolated from the venom of the Temple Pit Viper (Tropidolaemus wagleri). Waglerin-1 acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nAChR), blocking acetylcholine binding at the postsynaptic neuromuscular junction — the venom mechanism that causes flaccid paralysis in prey species. Pentapharm's design distilled this venom pharmacology into a much smaller synthetic pentapeptide (H-Gly-Pro-Arg-Pro-Ala-NH2) intended to retain receptor binding while being practical to formulate as a topical cosmetic. Marketed as Vialox alongside Pentapharm's other neuromuscular cosmeceutical (Syn-Ake), it was launched into the early 2000s 'natural Botox' product wave, with the snake-venom inspiration as a marketing centerpiece. An important caveat from the parent peptide pharmacology: waglerin-1 itself shows roughly 100-fold species selectivity favoring mouse over human nAChR, which complicates direct translation of receptor-binding assays from rodent or in vitro systems to human facial musculature. Independent academic literature on the synthetic pentapeptide remains thin — most efficacy claims trace back to manufacturer-associated studies — and the regulatory framing has remained firmly within the cosmeceutical category.
How It Works
When you frown or squint, nerves release acetylcholine to make facial muscles contract. Over years, these repeated contractions create permanent wrinkles. Vialox sits on the muscle's acetylcholine receptor like a key that fits but doesn't turn, blocking the real signal. The muscles partially relax, and the wrinkles they create soften and smooth out.
Vialox (H-Gly-Pro-Arg-Pro-Ala-NH2) is a synthetic pentapeptide fragment inspired by Waglerin-1 from Tropidolaemus wagleri venom. It acts as a reversible competitive antagonist at the alpha-epsilon (α/ε) subunit interface of the adult-type muscular nicotinic acetylcholine receptor (nAChR). By occupying the acetylcholine binding site on the postsynaptic membrane, Vialox prevents sodium channel opening, blocks membrane depolarization, and inhibits muscle contraction. In vitro: 71% contraction reduction at 1 minute, 58% at 2 hours. In vivo (28 days, twice daily, women aged 30-60): 49% wrinkle depth reduction, 47% skin roughness reduction. This postsynaptic mechanism is complementary to presynaptic approaches: Argireline and SNAP-8 inhibit SNARE complex assembly, while Pentapeptide-18 mimics enkephalins to reduce catecholamine release. Combining pre- and postsynaptic peptides targets multiple nodes of neuromuscular transmission.
Evidence Snapshot
Human Clinical Evidence
Limited. Manufacturer data (Pentapharm/DSM): 28-day in vivo study with twice-daily application in women aged 30-60 showed 49% wrinkle depth reduction and 47% skin roughness reduction. Not independently replicated in peer-reviewed trials. Referenced in multiple cosmeceutical review articles.
Animal / Preclinical
Limited. In vitro muscle contraction assays showed 71% reduction at 1 minute, 58% at 2 hours. Parent peptide Waglerin-1 is well-characterized for nAChR binding and subunit selectivity.
Mechanistic Rationale
Moderate. nAChR competitive antagonism is well-established for Waglerin-1. The truncated pentapeptide's ability to replicate this activity topically through intact skin is the key uncertainty. Waglerin-1 shows 100-fold species selectivity (mouse >> human), which may affect the fragment's efficacy at human receptors.
Research Gaps & Open Questions
What the current literature has not yet settled about Vialox:
- 01Independent, non-industry-funded human trials on Vialox specifically — the existing efficacy claims (49% wrinkle-depth reduction at 28 days) are dominated by Pentapharm/DSM-associated studies and have not been replicated in peer-reviewed independent trials.
- 02Direct head-to-head comparisons with botulinum toxin (the implicit comparator), Argireline, Syn-Ake, and Pentapeptide-18 at matched concentrations and durations.
- 03Real-world skin-penetration and target-site quantification — whether the pentapeptide actually reaches nAChRs in facial musculature in clinically meaningful concentrations from topical application is the central unresolved question.
- 04Translation of the waglerin-1 species-selectivity (100-fold mouse > human) to the truncated synthetic pentapeptide — whether Vialox retains the parent peptide's species bias or binds human nAChRs differently has not been characterized.
- 05Long-term human data — most published work spans 28-day windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
- 06Whether stacking Vialox with Syn-Ake produces additive benefit or redundant nAChR occupancy — the marketing pitch is synergy, but mechanism overlap suggests redundancy is at least as likely.
Forms & Administration
Vialox is used topically in cosmeceutical formulations at 0.05-0.3% concentration. Often combined with Argireline, Syn-Ake, and/or Matrixyl for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Cosmetic formulations typically include Vialox at 0.05–0.3% of the finished product — substantially lower than the percentages used for matrikine peptides (Matrixyl, Syn-Coll) or for hexa/octa-peptide neuromuscular peptides (Argireline, SNAP-8). Manufacturer guidance and most over-the-counter Vialox-containing serums fall within this range. Higher percentages on labels yield diminishing returns relative to formulation quality and vehicle choice.
Frequency
Applied topically once or twice daily to clean skin, targeting expression-line areas (forehead, glabella, crow's feet). Manufacturer protocols used twice-daily application for 28 days before measuring wrinkle-depth and skin roughness endpoints.
Cycle Length
Continuous indefinite use. Vialox is a maintenance cosmetic active — the competitive, reversible nAChR antagonism only operates while peptide is present at the receptor, so measurable benefit requires continued application. No cycling strategy is described in the cosmetic literature.
Protocol Notes
Skin penetration is the central practical caveat. The synthetic pentapeptide is hydrophilic and faces the same stratum corneum barrier as other cosmetic peptides. The pharmacological target — nAChRs at neuromuscular junctions in facial musculature — sits well below the epidermal layers that topical peptides typically reach, which is the fundamental gap between in vitro receptor-binding assays (71% contraction reduction at 1 minute, 58% at 2 hours in isolated tissue preparations) and modest in vivo wrinkle-depth effects. Vialox is commonly stacked with Argireline (presynaptic SNARE-complex inhibition) on the rationale that hitting the neuromuscular junction from both pre- and postsynaptic sides should produce additive effects. It is also frequently combined with Syn-Ake — but both Vialox and Syn-Ake target essentially the same postsynaptic nAChR site, so this particular stack risks redundant receptor occupancy rather than additive benefit. Pairing with matrikine peptides (Matrixyl, Syn-Coll) for collagen support combines independent mechanisms more cleanly. The waglerin-1 species-selectivity caveat (100-fold mouse > human) is worth keeping in mind: in vitro and rodent receptor data on the parent venom peptide do not translate directly to expected potency at human nAChRs.
Vialox is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Do not inject cosmetic peptide products — there is no authorized injectable category for Vialox and documented infection risk exists for unlicensed injection of cosmetic peptides.
Timeline of Effects
Onset
Manufacturer-sponsored studies typically begin to report measurable wrinkle-depth and skin-roughness reduction within 2 weeks of twice-daily application. Immediate 'tightening' or smoothing sensations within minutes of application come from film-forming polymers and humectants in the vehicle, not from real-time receptor blockade.
Peak Effect
Maximum measured effect in the manufacturer's 28-day in vivo study (women aged 30–60, twice-daily application) was reported at approximately 49% wrinkle-depth reduction and 47% skin-roughness reduction. These figures sit at the high end of cosmetic peptide claims and have not been independently replicated in peer-reviewed trials — they should be interpreted with manufacturer-funding context. For comparison, botulinum toxin injection reduces dynamic wrinkle severity by 50–80% within days; topical Vialox effects, where present, develop over weeks and are softer in real-world clinical experience.
After Discontinuation
Effects recede over weeks as the peptide is cleared and nAChR function returns to baseline. Most users describe a gradual return toward baseline expression-line depth within 4–8 weeks of stopping use. There is no described withdrawal or rebound pattern.
Common Questions
Who Vialox Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential and any systemic absorption.
- •Known hypersensitivity to Vialox or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); contact dermatitis is uncommon but reported.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy, and the receptor-targeting mechanism makes a conservative default to minimize use during this window reasonable.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-wrinkle peptides.
- •Do not inject cosmetic Vialox preparations — these are not sterile injectable products, not manufactured under injectable standards, and there is no clinical basis for injection.
- •Patients with pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) should consult a clinician before using nAChR-targeting cosmetic peptides, even though systemic exposure from topical use is expected to be negligible.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Vialox are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The practical interaction space is topical layering with other actives. Vialox is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is common and marketed as synergistic on the rationale that pre- and postsynaptic mechanisms hit different points in the same neuromuscular cascade. Stacking with Syn-Ake is common but raises a redundancy question — both Vialox and Syn-Ake target the postsynaptic nAChR, so additive benefit is theoretically capped. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Vialox can reduce peptide activity at the surface and increase irritation, so spacing is sensible. There is no documented concern with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. Patients receiving botulinum toxin injection generally do not need to stop Vialox beforehand.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Clinical data is primarily from manufacturer-sponsored studies (Pentapharm/DSM)
- • Topical efficacy limited by skin penetration — not as potent as injectable neurotoxins
- • Waglerin-1 shows 100-fold species selectivity (mouse > human nAChR) — truncated fragment binding at human receptors may differ
What We Don't Know
Long-term effects of chronic topical nAChR antagonism on facial muscles are unstudied. Whether meaningful receptor blockade occurs through intact skin at cosmeceutical concentrations is debated. Independent clinical replication beyond manufacturer data is limited.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Vialox (pentapeptide-3) is INCI-listed and appears in many over-the-counter anti-wrinkle products. Not approved as a drug for wrinkles or any other medical indication — labels are limited to cosmetic appearance claims. The 'snake venom' marketing language describes biomimetic design inspiration, not source material; the ingredient is fully synthetic.
International
Permitted as a cosmetic ingredient across the EU (CosIng database), UK, Canada, Australia, Japan, and most major markets. Cosmetic ingredient safety reviews have not raised concerns at typical formulation levels.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides have negligible systemic exposure relevant to performance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Vialox is 'natural Botox' and produces comparable results to injection.
Reality
The marketing framing is misleading. Vialox competitively and reversibly blocks the muscle nicotinic acetylcholine receptor; botulinum toxin enzymatically cleaves SNARE proteins inside nerve terminals to abolish acetylcholine release entirely. Botulinum toxin produces 50–80% wrinkle reduction within days; topical Vialox claims of comparable percentages come from manufacturer-sponsored studies that have not been independently replicated. Vialox does not substitute for injection.
Myth
Vialox contains real snake venom.
Reality
Vialox is a fully synthetic pentapeptide manufactured in a lab. It was designed as a fragment inspired by waglerin-1 from Temple Pit Viper venom, but contains no animal-derived material and no actual venom. The 'snake venom peptide' marketing describes biomimetic design inspiration, not source.
Myth
Manufacturer's 49% wrinkle-reduction figure means Vialox nearly halves wrinkle appearance for any user.
Reality
The percentage refers to measured wrinkle-depth reduction under standardized imaging in a manufacturer-sponsored 28-day study. Real-world experience at typical product concentrations and use patterns is substantially more variable, and independent peer-reviewed replication of the 49% figure has not been published. Most users notice subtle smoothing and softening of expression lines rather than dramatic depth reduction.
Myth
Stacking Vialox with Syn-Ake doubles the muscle-relaxing effect.
Reality
Vialox and Syn-Ake both target the postsynaptic muscular nicotinic acetylcholine receptor. Stacking them likely produces redundant occupancy of the same target rather than additive benefit. Combining a postsynaptic blocker with a presynaptic inhibitor (Argireline, SNAP-8, or Pentapeptide-18) is mechanistically more complementary, but clinical evidence that multi-peptide stacks meaningfully outperform a single well-formulated cosmetic peptide is limited.
Myth
Vialox can be safely injected for a stronger effect.
Reality
Cosmetic Vialox preparations are not sterile injectable products, not manufactured under injectable standards, and there is no authorized injectable category. Injecting cosmetic peptide products carries documented infection risk — published case reports exist for related cosmetic peptides causing serious facial mycobacterial infection after unlicensed injection.
Published Research
4 studiesAnti-ageing peptides and proteins for topical applications: a review.
Role of topical peptides in preventing or treating aged skin.
Cosmeceutical peptides.
Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors.
Quick Facts
- Class
- Cosmeceutical Peptide
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 4PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.